Aptinyx Inc. (APTX) stock surged by 7.33% at the last trading close while the APTX stock continued to show gains by 1.86% in the pre-market trading as well after APTX announced that it has recommenced the screening of patients in a Phase 2 study of NYX-458. Aptinyx is a clinical-stage biopharmaceutical company that develops and commercializes patented synthetic small molecules for the cure of brain and nervous system disorders.
What is happening?
Today on April 6, 2021, APTX stock has reported that patient screening for a Phase 2 trial of NYX-458 in patients with moderate cognitive impairment, mild dementia associated with Parkinson’s disease, and dementia with Lewy bodies has started again. The results of this study are expected to be released in the second half of 2022, according to the company.
NYX-458 is a novel oral NMDA receptor modulator that is currently being studied in clinical trials for the cure of cognitive dysfunction in Parkinson’s disease and dementia with Lewy bodies. In a design that is closely comparable to Parkinson’s disease in humans, NYX-458 has been shown to reverse cognitive deficits in nonhuman primates.
Outlook of Phase 2 study
The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled trial in about 100 patients with moderate cognitive impairment or mild dementia linked with Parkinson’s disease or prodromal or indicate dementia with Lewy bodies to assess the safety and possible cognitive benefits of NYX-458.
Over the course of 12-week duration, the study aims to compare daily oral dosing of NYX-458 30 mg to placebo. NYX-458’s overall safety and efficacy in patients will be assessed, as well as the drug’s possible cognitive benefits across various neurocognitive endpoints based on the concentration, memory, and executive function.
Furthermore,
The CEO of Aptinyx Norbert Riedel said that they are hoping for positive results from the evaluation of NYX-458 in patients who are suffering from cognitive impairment. He also added that current treatments for these patients often fail to provide significant results, and new treatment approaches are desperately needed. They also assume that NYX-458’s mechanism is ideally suited to solve these patients’ cognitive deficits, and they look forward to building on the convincing preclinical evidence we’ve gathered so far with NYX-458.
